Benzodiazepines: toxic serum concentrations in positive enzyme immunoassay responses.
A total of 588 blood specimens collected in an emergency unit were screened for benzodiazepines (BZDs) using enzyme-multiplied immunoassay and gas chromatography. Two-hundred eighty-five samples were positive for BZDs, and 303 samples that were negative by EMIT included 20 samples with BZDs detectable by gas-liquid chromatography. A total of 15 BZDs were identified, and the most frequently occurring were nordiazepam, bromazepam, diazepam, and alprazolam. Individual BZDs were found in 74% of cases, but some samples contained two, three, or even four BZDs. There is a risk of missing intoxication by BZDs with low therapeutic range and/or low cross-reactivity (alprazolam, bromazepam, flunitrazepam). There is a risk of misinterpreting a positive result for some BZDs with high therapeutic range and/or high cross-reactivity (nordiazepam), which may reflect a pharmacologically ineffective concentration. A semiquantitative analysis is inappropriate even when the identity of BZD is known. Immunoassays are the only methods presently available for use in emergencies, but physicians must be clearly informed of their limitations and interpret results with caution.
Divanon
F
F
Evaluation and Information Center of Drug Dependences, Laboratory of Pharmacology, CHU Côte de Nacre, Caen, France.
Debruyne
D
D
Moulin
M
M
Leroyer
R
R
D000525:Alprazolam / Q000097:blood; D001569:Benzodiazepines / Q000097:blood* / Q000506:poisoning; D001960:Bromazepam / Q000097:blood; D002849:Chromatography, Gas; D003975:Diazepam / Q000097:blood; D004347:Drug Interactions; D062787:Drug Overdose / Q000097:blood / Q000175:diagnosis*; D017248:Enzyme Multiplied Immunoassay Technique; D005445:Flunitrazepam / Q000097:blood; D006801:Humans; D007124:Immunoenzyme Techniques; D003708:Nordazepam / Q000097:blood
D001569:Benzodiazepines; D005445:Flunitrazepam; D003708:Nordazepam; D003975:Diazepam; D001960:Bromazepam; D000525:Alprazolam